At Houston's MD Anderson Cancer Center, oncologist John Heymach and his team have documented something rare in the fight against lung cancer: a targeted drug that decisively outperforms the standard treatment that patients have relied on for years. Sunvozertinib, a next-generation therapy taken as a daily pill, extended the time without disease progression to more than 10 months for patients with advanced non-small cell lung cancer driven by EGFR exon20ins mutations—a notoriously stubborn form of the disease that has long resisted conventional options.
For years, patients with these specific mutations have faced a cruel reality. Earlier generations of targeted therapies simply didn't work well against their cancer, and chemotherapy, though standard, offered limited control. EGFR exon20ins mutations occur in a small subset of lung cancer patients, but for those who carry them, the options have been grim. Sunvozertinib was designed precisely for this purpose: to block the abnormal cell signaling caused by these mutations in a way that older drugs cannot.
The evidence comes from the Phase III WU-KONG28 trial, an international study that enrolled 324 patients and randomly assigned them to either sunvozertinib or standard platinum-based chemotherapy with carboplatin and pemetrexed. The results, presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine, are striking. Sunvozertinib extended progression-free survival to over 10 months compared to 7.5 months with chemotherapy alone. More dramatically, tumors shrank in 58.9% of patients receiving sunvozertinib versus just 31.1% on chemotherapy—nearly doubling the response rate. Those gains lasted, with responses persisting for a median of 11.2 months on sunvozertinib versus 7.1 months on chemotherapy.
What makes this advance particularly meaningful is the practicality it offers. Sunvozertinib is an oral medication, meaning patients take it as a pill at home rather than spending hours in clinics receiving intravenous chemotherapy. The safety profile remained consistent with earlier studies, with only 7.4% of patients discontinuing treatment due to drug-related side effects and no treatment-related deaths recorded. As Heymach noted, sunvozertinib offers "a new, much-needed option for those starting treatment," filling a gap that has haunted this patient population for far too long.
The FDA granted sunvozertinib accelerated approval in August 2023 for patients with advanced NSCLC and EGFR exon20ins mutations who had previously received chemotherapy. Now, with the WU-KONG28 results, the evidence shows it should be considered a first-line choice—the treatment doctors reach for first, before chemotherapy. The trial did allow patients on chemotherapy to switch to sunvozertinib if their disease progressed, and many did, though overall survival data remain pending. Still, the progression-free survival advantage and tumor response rates paint a clear picture of a drug that works meaningfully better for this hard-to-treat group.